"The procedure that I had got me back to doing the things I like to do that I couldn't do before."
Betty Poe couldn’t walk to her mailbox. She couldn’t work in her beloved garden. All she could do was sit in her recliner, wondering if her life would ever improve. Then Betty Poe underwent a revolutionary new cardiac procedure. That changed everything.
About the MitraClip
Patients with leaky mitral valves who are frail, older or have multiple medical issues now may be treated with an innovative device called a MitraClip. First approved by the FDA in 2013 for patients with severe and degenerative mitral regurgitation who also had heart failure symptoms resulting from an abnormality of the mitral valve. In 2019, the device was approved for an expanded use in patients with heart failure symptoms with moderate to severe mitral regurgitation due to diminished left heart function.
Because this is a minimally invasive procedure, patients can typically leave the hospital 2-3 days after the procedure. Significantly, clinical trials evaluating the device’s effectiveness found that the risk of being re-hospitalized for heart failure symptoms was reduced in about 47% of patients who had the MitraClip procedure versus patients who did not receive the device.